Opexa Therapeutics (OPXA) Chief Scientific Officer Invited As Guest Speaker At The Phacilitate Cell & Gene Therapy Forum
1/23/2014 9:19:51 AM
THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Don Healey, Ph.D., Opexa’s Chief Scientific Officer, has been invited as a guest speaker to participate in the Phacilitate Cell & Gene Therapy Forum. The event will take place January 27-29, 2014, at The Grand Hyatt in Washington, DC.
Help employers find you! Check out all the jobs and post your resume.
comments powered by